

Navigating Experimental Arms in Subtype Studies: Strategies for Precision and Clarity

Company: STATECS

Presenter: Narek

Torosyan

Agenda

- ≡ Introduction to Subtype Studies
- ≡ Design Complexity & Rationale
- ≡ Statistical Considerations
- ≡ Bias Prevention Strategies
- ≡ Regulatory Clarity & Expectations
- ≡ Methodological Recommendations
- ≡ Case Examples
- ≡ Discussion & Synthesis
- ≡ Discussion Questions

≡ Introduction to Subtype Studies

Focused Subgroups

Trials target specific patient groups defined by genetics, biomarkers or clinical features, rather than a mixed population.

Precision Medicine Goal


Match the right therapy to the right patients, generating clear, targeted evidence.

Rising Prominence

Subtype trials are increasingly common as we move toward personalized treatment strategies.

Complexity of Multiple Arms

Evaluating several subgroups within one study allows comprehensive insights, but introduces design and operational challenges.



≡ Design Complexity & Rationale

Tailored Arms for Precision

The rationale for using multiple arms is to evaluate treatments across subpopulations within a single trial, maximizing information gained.

Comparability Challenges


Running multiple subgroup-specific arms introduces design and analytical complexity complicating comparisons.

Operational Strain

Multiple arms require careful coordination, from maintaining balanced enrollment to ensuring logistical feasibility.


Need for Rigorous Planning

Meticulous upfront planning is created to prevent clarity and scientific credibility.



≡ Key Statistical Considerations

- 01 Multiplicity Control**
Testing multiple hypotheses increases the risk of false positives.
- 02 Power & Sample Size**
Dividing participants into several arms can dilute statistical power.
- 03 Consistency Across Arms**
Standardizing endpoints and eligibility criteria enables meaningful comparisons.
- 04 Efficiency vs Complexity**
Statistical planning must balance thoroughness with simplicity.



≡ Bias Prevention Strategies

01

Pre-specification

Clearly define
subgroups hypotheses
and analysis plans
before the trial starts

02

Stratified Randomization

Use stratified
randomization or block
design based on key
biomarkers or subtype
classifications

03

Proven in Practice

Maintain blinding
whenever possible and
include appropriate
control arms or
comparators

Regulatory Clarity & Expectations

Transparent Analysis Plan

Regulators expect a transparent statistical analysis plan that details how each arm and subgroup will be evaluated.

Pre-Defined subgroup Definitions

Clearly document the rationale and definition for each subtype subgroup at the design stage.

Align with Guidance (ICH E9/R1)

Design the trial in accordance with regulatory guidelines and frameworks (e.g., use the ICH E9(R1) estimated framework).

Regulator Engagement

Proactively engage with regulatory agencies early, if possible, to discuss the multi-arm.



Methodological Recommendations

- **Clear Subtype Definitions**

Pre-specify precise subtype criteria and corresponding hypotheses at the outset

- **Adaptive Design Elements**

Incorporate adaptive methods to improve efficiency

- **Harmonize Endpoints & Eligibility**

Use consistent endpoints and inclusion/exclusion criteria across arms

- **Multiplicity Mitigation**

Plan for multiplicity control using hierarchical or Bayesian adjustments

- **Transparent Reporting**

Maintain transparent reporting and documentation throughout



≡ Real-Word Case Examples (Multi-Arm Subtype Trials)

TAILORx Trial (Oncology, Breast Cancer – NCI, 2015)

Design: Focused on women with hormone-receptor-positive, HER2-negative breast cancer. Patients were classified by 21-gene recurrence score (low, intermediate, high risk).

Bias Prevention: Pre-specified subtypes, randomized intermediate group, blinded genomic assay results.

Impact: Demonstrated tailored chemotherapy strategies, influencing treatment guidelines globally.

CheckMate 227 Trial (Immuno-oncology, Lung Cancer – BMS, 2019)

Design: Stratified patients by PD-L1 expression levels; arms included nivolumab alone, nivolumab + ipilimumab, and chemotherapy.

Bias Prevention: Stratified randomization, harmonized endpoints (OS, PFS), maintained blinding.

Impact: Provided a regulatory foundation for immunotherapy approvals in biomarker-defined NSCLC populations.

RUBY Trial (Rare Disease, Uterine Cancer – 2023)

Design: Patients were stratified based on mismatch repair status, comparing dMMR versus pMMR subgroups.

Bias Prevention: Pre-specified endpoints and hierarchical testing ensured unbiased, statistically controlled evaluation of outcomes.

Impact: Key findings led to EMA and FDA approval of the study drug for dMMR endometrial cancer.

≡ Discussion & Synthesis of Best Practices

01

Balance Precision vs Feasibility

Managing experimental arms in subtype trials requires balancing precision and feasibility.

02

Integration of Best Practices

Key strategies, pre-specifying subgroups, adaptive allocation, harmonizing endpoints and ensure transparency.

03

Advancing Precision Medicine

Well-designed multi-arm subtype trials produce credible findings translating genomic/biomarker insights into approved therapeutics.

≡ Sample Discussion Questions

Q1 How can adaptive trial designs be optimized to maintain statistical power when patient subgroups are unevenly represented?

Q2 What strategies are most effective for balancing multiplicity control with operational feasibility in subtype studies?

Q3 How can regulators and sponsors align expectations around subgroup analysis to ensure clarity and acceptance of results?



These questions encourage critical thinking about applying best practices to real-world multi-arm subtype trials—balancing statistical rigor, operational feasibility, and regulatory expectations to ensure scientifically sound and practically executable study designs.

≡ Conclusions & Takeaways

With careful statistical planning, operational foresight and proactive regulatory alignment, multi-arm trials can deliver precise and credible evidence on treatment effects in specific subgroups.

Success requires upfront investment in design. e.g., solid power calculations per arm, clear analysis protocols, and bias mitigation plans.

By learning from past trials and adopting structured methodologies, researchers can design subtype studies that maintain clarity, sufficient power and withstand regulatory scrutiny.

In practice, this means rigorously controlling errors (statistical and bias-related) and transparently reporting results.

Properly managed multi-arm subtype trials are cornerstone of precision medicine, they enable us to identify the right therapy for the right group of patients, while providing evidence that is robust and acceptable to regulators.



**Opportunity
vs Challenge**



**Importance
of Careful
Planning**



**Ensuring
Reliable
Outcomes**



**Takeaway
Message**



Properly managed
multi-arm subtype
trials are a cornerstone
of precision medicine



Thank You!

Let's keep in touch!



Narek Torosyan

*Associate Director Statistical
Programming*